Skip to main content
. 2017 Dec 9;9(1):982–994. doi: 10.18632/oncotarget.23140

Figure 6. EP3 antagonist inhibits migration ability of RL95-2 cells.

Figure 6

(A) Representative images show cell migration into the wounded area in vehicle treated group and 1 μM L-798,106 treated group. (B) Histogram compares migration in vehicle treated group and 1 μM L-798,106 treated group. Results were normalized to cell proliferation of control group. Bar graph represents mean ± SEM (n = 4). *p < 0.05 (compared to vehicle treated control group).